glp-1 covid Could weight loss drugs treat long-haul COVID? GLP-1 Pipeline Update: November 2024

Apart from their utility in the management of T2D, injectable liraglutide and semaglutide have gained licences for the management of overweight/obesity in people without T2D at higher doses than used for treatment of T2D

This dual action is being explored in research as a potential way to better understand hormone release patterns, tissue remodeling processes, and energy distribution across biological systems

For individuals who do not respond to GLP-1, this tailored, phenotype-driven methodology within a stepped-care framework guarantees more precise and efficacious interventions, affirming the early use of medication as a scientifically substantiated and personalised strategy rather than a mere pragmatic option

Fatima, who is 38 years old, was diagnosed with ADHD 12 years ago